Neurovax

NeuroVax is an investigational immunotherapy drug that is currently being studied for its potential use in the treatment of multiple sclerosis (MS) and other autoimmune diseases. It is developed by Immune Response BioPharma, Inc.

Mechanism of Action

NeuroVax is designed to stimulate the production of T-cells, a type of white blood cell that plays a key role in the body's immune response. Specifically, it targets T-cell Receptor (TCR) peptide families that have been implicated in MS and other autoimmune diseases. By boosting the body's natural immune response, NeuroVax may help to control the abnormal immune activity that characterizes these conditions.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of NeuroVax. These studies have shown promising results, with some patients experiencing a reduction in disease activity and an improvement in neurological function. However, further research is needed to confirm these findings and to determine the optimal dosing regimen for this drug.

Potential Applications

In addition to MS, NeuroVax is also being investigated for its potential use in the treatment of other autoimmune diseases, including rheumatoid arthritis and psoriasis. These conditions, like MS, are characterized by abnormal immune activity, and it is hoped that NeuroVax may offer a new treatment option for patients who do not respond to existing therapies.

See Also

• Immunotherapy
• Multiple Sclerosis
• Autoimmune Diseases
• Clinical Trials

References

Neurovax Resources
Latest articles Most recent articles Ongoing trials	Wikipedia